For detecting 87 mutations in the PI3K-AKT pathway

qBiomarker Somatic Mutation PCR Array: Human PI3K-AKT Signaling Pathway The Human PI3K-AKT Signaling Pathway qBiomarker Somatic Mutation PCR Array is a translational research tool that allows rapid and accurate profiling of the somatic mutation status for key genes in the PI3K-PTEN pathway: AKT1, AKT3, PIK3CA, PIK3R1, PIK3R5, PTEN, and STK11/LKB1. Components in this pathway are frequently mutated in human cancers (mutated in >30% solid tumor types) and therefore warrant extensive investigation to enhance the understanding of carcinogenesis and identify potential drug targets. The utility of individual and multiple somatic mutation status information in identifying key signaling transduction disruptions has been demonstrated in numerous research studies. For example, the mutation status of the EGFR and KRAS genes can predict the physiological response to certain drugs targeting these molecules. The Human PI3K-AKT Signaling Pathway qBiomarker Somatic Mutation PCR Array, with its comprehensive content coverage, is designed for studying mutations in the context of the PI3K-Akt pathway and provides the potential to discover and verify drug target biomarkers for a variety of human cancers involving the PI3K-Akt signaling pathway and downstream effectors. This array includes 87 DNA sequence mutation assays designed to detect the most frequent, functionally verified, and biologically significant mutations in the PI3K-AKT pathway. These mutations were chosen from curated, comprehensive, somatic mutation databases and peer-reviewed scientific literature. The simplicity of the product format and operating procedure allows routine somatic mutation profiling in any research laboratory with access to real-time PCR instruments.
The qBiomarker Somatic Mutation PCR Arrays are intended for molecular biology applications. This product is not intended for the diagnosis, prevention, or treatment of a disease    

AKT genes: 
The mutation assays detects the best known AKT mutation, c.49G>A, p.E17K (AKT1; a PH domain mutation that results in constitutive targeting of AKT1 to plasma membrane), the activating mutations c.145G>A, p.E49K (AKT1) and c.511G>A, p.G171R (AKT3).
PIK3CA (phosphatidylinositol 3-kinase catalytic subunit) gene:
The mutation assays covered on this panel can detect 37 most frequently occurring PIK3CA mutations that are mainly clustered in the kinase domain (activating mutations) and in the P539-E545 region and vicinity, which are helical domain mutations that mimic activation by growth factors. The assays allow a comprehensive profiling of PIK3CA mutations that have been identified in a variety of cancers.
PIK3R1 and PIK3R5 (PI3K regulatory subunit) genes:
Two recurrent disinhibitory (c.1126G>A, p.G376R and c.1690A>G, p.N564D) mutations in PIK3R1 and a recurrent oncogenic mutation in PIK3R5 are included. 
PTEN gene:
Included on the panel are 33 most commonly detected PTEN loss-of-function mutations that are mainly due to truncation or point mutation-caused phosphatase inactivation. 
STK11/LKB1 gene:
Included on the panel are 11 most commonly detected STK11/LKB1 inactivation mutations that are mainly due to truncation or point mutation.